January 17, 2018 09:45 AM EST

France's Owkin raises $11M Series A for AI-aided drug development; AstraZeneca expands discovery deal with X-Chem

Amber Tong

→ Riding on the artificial intelligence buzz in clinical research, Owkin has completed a $11 million Series A funding round for its predictive analytics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

France's Owkin raises $11M Series A for AI-aided drug development; AstraZeneca expands discovery deal with X-Chem

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

France's Owkin rais­es $11M Se­ries A for AI-aid­ed drug de­vel­op­ment; As­traZeneca ex­pands dis­cov­ery deal with X-Chem

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

France's Owkin raises $11M Series A for AI-aided drug development; AstraZeneca expands discovery deal with X-Chem

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA